LOS ANGELES, CA - VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, announced the appointment of Raju Willener as chief financial officer, effective immediately. Willener brings more than three decades of international financial leadership experience spanning global capital markets, investment banking, corporate finance, asset management and strategic leadership. He will report to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to support the company's capital strategy, strategic opportunities and continued development of its proprietary BiTAC(R) technology platform and oncology pipeline.
Prior to joining VERAXA, Willener served as director of corporate development at Exentis Group AG before being appointed CFO in 2025, where he led M&A initiatives, financial strategy and key corporate functions. Earlier in his career, he held senior executive and investment positions overseeing areas including corporate finance, capital markets, investor relations and investment portfolios exceeding CHF 30 billion in assets under management. This extensive background will be instrumental as VERAXA navigates the complex financial landscape of biotech development.
This appointment comes at a critical time for VERAXA, as the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. The addition of a seasoned CFO like Willener is likely to bolster investor confidence and provide the financial oversight necessary to support the company's ambitious growth plans. The move is particularly significant given the capital-intensive nature of oncology drug development, where strategic financial management can be a key differentiator between success and failure.
Willener's expertise in capital markets and corporate finance will be crucial as VERAXA seeks to fund its research and development efforts. His track record in managing large investment portfolios and leading M&A initiatives suggests he will play a pivotal role in shaping the company's financial strategy and exploring potential partnerships or funding opportunities. The company's proprietary BiTAC technology, which is based on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), holds promise for more effective cancer treatments, and strong financial leadership will ensure that the company can continue to invest in its development.
For investors and industry observers, this appointment signals VERAXA's commitment to building a strong management team and positioning itself for future growth. The company's focus on bispecific T cell engagers and bispecific ADCs places it in a competitive but rapidly evolving field, and having a CFO with deep financial expertise will help navigate the challenges ahead. As VERAXA moves its pipeline forward, the strategic guidance of its new CFO will be essential in realizing the potential of its innovative therapies.
For more information on VERAXA and its pipeline, please visit the company's newsroom at https://ibn.fm/VRXA.
